Actively Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Led by Canadian Cancer Trials Group · Updated on 2026-03-27
720
Participants Needed
10
Research Sites
4 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating targeted therapies for cancer patients whose tumors have specific abnormal gene changes. This study, called CAPTUR, aims to understand how these targeted drugs affect patients and their cancers. It focuses on patients with incurable metastatic solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma who have identified 'druggable' genetic changes in their cancers. The study tests several commercially available targeted drugs matched to the genetic abnormalities found in patients' tumors. The treatments include various oral and intravenous medications such as Olaparib, Dasatinib, Nivolumab plus Ipilimumab, and others, each given with specific dosing schedules. The trial is non-randomized and includes groups based on different genetic targets; some groups are closed and no longer recruiting. Participants will be monitored over time to assess tumor response, side effects, and progression-free survival. Researchers will measure objective response rates after up to four years. Patients undergo tumor profiling to identify genetic changes and must meet organ function and performance status requirements. Follow-up includes safety assessments and evaluation of treatment effects during the study period.
CONDITIONS
Brief Title
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult (18 years or older) with incurable metastatic solid tumor (excluding primary brain tumors), multiple myeloma, or B cell non-Hodgkin lymphoma (excluding CLL, SLL, and HCL) with no standard life-prolonging treatment available or refused such treatment
- ECOG performance status between 0 and 2
- Normal organ function including neutrophil count, platelet count, bilirubin, liver enzymes, and kidney function within specified limits
- Measurable disease present
- Tumor genomic or protein expression testing available showing a potentially actionable genetic variant
- Signed informed consent prior to screening
- Accessible for treatment and follow-up at participating centers within reasonable geographic limits
- Women and men of childbearing potential agree to use highly effective contraception
You will not qualify if you...
- Prior or concurrent malignancy that may interfere with safety or efficacy assessment
- Ongoing toxicity grade 2 or higher from prior anti-tumor treatment except certain corrected conditions; peripheral neuropathy grade 3 or higher excluded
- Concurrent anti-cancer therapies except supportive care medications started at least one month prior or ongoing castration-intent therapy for prostate cancer
- Known active progressive brain metastases; previously treated brain metastases must be stable and off steroids or only physiological doses
- Significant pre-existing cardiac conditions including uncontrolled angina, arrhythmias, or symptomatic heart failure
- Left ventricular ejection fraction below 40%
- Stroke or acute myocardial infarction within three months prior to screening
- Acute gastrointestinal bleeding within one month prior to screening
- Any other significant medical condition making participation undesirable or compliance difficult
- Lactating and nursing women
- Not meeting drug-specific eligibility for the selected treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Participants receive targeted cancer drugs based on their tumor's genetic profile, taking medications such as Olaparib, Dasatinib, Nivolumab plus Ipilimumab, and others as prescribed.
Visits occur regularly throughout treatment as per drug administration schedule
Duration - Up to 4 years
Participants are monitored for response to treatment, side effects, and progression of disease after treatment ends.
Periodic visits for assessment and safety monitoring
Trial Site Locations
Total: 10 locations
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
2
BCCA - Kelowna
Kelowna, British Columbia, Canada, V1Y 5L3
Actively Recruiting
3
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
4
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L 2V7
Actively Recruiting
5
London Health Sciences Centre Research Inc.
London, Ontario, Canada, N6A 5W9
Actively Recruiting
6
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
Actively Recruiting
7
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
8
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
9
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Actively Recruiting
10
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4
Actively Recruiting
Research Team
J
Janet Dancey
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
14
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here